NanoVibronix, Inc., a medical technology company, has announced the pricing of a $10 million public offering involving Series G Convertible Preferred Stock and Warrants. The offering includes approximately 400,000 shares of Preferred Stock and Warrants to purchase up to 4,901,961 shares of common stock. The proceeds from this offering are intended to be used for the redemption of the principal amount of an outstanding debenture and a partial repayment of an outstanding note, alongside general corporate purposes. The transaction is expected to close around May 19, 2025, contingent upon customary closing conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.